EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease

Liang-Yu Lin, Ting-Ting Chang, Hsin-Bang Leu, Chin-Chou Huang, Tao-Cheng Wu, Ruey-Hsin Chou, Po-Hsun Huang, Wei-Hsian Yin, Wei-Kung Tseng, Yen-Wen Wu, Tsung-Hsien Lin, Hung-I Yeh und 4 weitere

Clinical Research in Cardiology · 2025-08 · 114 (8) · 952-968

DOI: 10.1007/s00392-024-02458-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 13.05.2024. Verfasst von Liang-Yu Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 11217, Ta…. Hauptthemen laut MEDLINE: Proteoglycans, Coronary Artery Disease, Neoplasm Proteins, Endothelial Progenitor Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Veterans General Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Both the clinical and mechanistic impacts of endocan were not well elucidated especially in coronary artery disease (CAD).

Objective

This study aimed to investigate the prognostic and potential pathological role of endocan for cardiovascular (CV) events in stable CAD patients.

Methods

A total of 1,071 stable CAD patients with previous percutaneous coronary intervention (PCI) were enrolled prospectively in a nationwide Biosignature study. Another cohort of 76 CAD patients with or without PCI were enrolled for validation. Baseline biomarkers including endocan level was measured and total CV events especially hard CV events (including CV mortality, non-fatal myocardial infection and stroke) during follow-up were identified. Circulating endothelial progenitor cells (EPCs) as an in vivo biological contributor to vascular repairment from CAD patients were used for the in vitro functional study.

Results

After 24 months, there were 42 patients (3.92%) with hard CV events and 207 (19.3%) with total CV events in the study group. The incidence of both events was increased with the tertiles of baseline endocan level (hard events: 1.7%,3.4%, and 6.7% in 1st,2nd, and 3rd tertile respectively, p = 0.002; total events: 13.8%vs.16.2%vs.28.0%, p < 0.0001). Multivariate regression analysis revealed the independent association of endocan level with total and hard CV events. These findings were validated in another cohort with a 5-year follow-up. Furthermore, in vitro inhibition of endocan improved cell migration and tube formation capacities, and reduced cell adhesiveness of EPCs from CAD patients.

Conclusions

Endocan might be a novel prognostic indicator, mechanistic mediator, and potential therapeutic target for clinical CAD. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteoglycansCoronary Artery DiseaseNeoplasm ProteinsEndothelial Progenitor CellsHumansMaleFemalePrognosisMiddle AgedProspective StudiesBiomarkersAgedFollow-Up StudiesPercutaneous Coronary Intervention

Stichwörter der Autor:innen

Cardiovascular diseaseCoronary artery diseaseEndocanEndothelial progenitor cell

Substanzen

ESM1 protein, humanProteoglycansNeoplasm ProteinsBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 11217, Taiwan. linly@vghtpe.gov.tw.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. linly@vghtpe.gov.tw.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Förderung

  • Taipei Veterans General Hospital
  • National Science and Technology Council

Zitieren

APA

Lin, L. Y., Chang, T. T., Leu, H. B., Huang, C. C., Wu, T. C., Chou, R. H., Huang, P. H., Yin, W. H., Tseng, W. K., Wu, Y. W., Lin, T. H., Yeh, H. I., Chang, K. C., Wang, J. H., Wu, C. C., & Chen, J. W. (2025). Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease. Clinical Research in Cardiology, 114(8), 952-968. https://doi.org/10.1007/s00392-024-02458-7

Vancouver

Lin LY, Chang TT, Leu HB, Huang CC, Wu TC, Chou RH, et al. Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease. Clinical Research in Cardiology. 2025;114(8):952-968. doi:10.1007/s00392-024-02458-7

BibTeX
@article{Lin2025,
  author = {Lin, Liang-Yu and Chang, Ting-Ting and Leu, Hsin-Bang and Huang, Chin-Chou and Wu, Tao-Cheng and Chou, Ruey-Hsin and Huang, Po-Hsun and Yin, Wei-Hsian and Tseng, Wei-Kung and Wu, Yen-Wen and Lin, Tsung-Hsien and Yeh, Hung-I and Chang, Kuan-Cheng and Wang, Ji-Hung and Wu, Chau-Chung and Chen, Jaw-Wen},
  title = {Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  volume = {114},
  number = {8},
  pages = {952--968},
  doi = {10.1007/s00392-024-02458-7}
}
Kostenlos starten →